Parkinson's disease (PD) is a neurodegenerative disease with significant unmet medical needs. The current dopamine-centered treatments aim to restore motor functions of patients without slowing the disease progression. Long-term usage of these drugs is associated with diminished efficacy, motor fluctuation, and dyskinesia. Furthermore, the nonmotor features associated with PD such as sleep disorder, pain, and psychiatric symptoms are poorly addressed by the dopaminergic treatments. Adenosine receptor A2A antagonists have emerged as potential treatment for PD in the past decade. Here we summarize the recent work (2015-2018) on adenosine receptor A2A antagonists and discuss the challenge and opportunity for the treatment of PD.

中文翻译：

---

腺苷A2A受体拮抗剂治疗帕金森氏病的进展：最近的更新和挑战。

帕金森氏病（PD）是一种神经退行性疾病，医疗需求严重不足。当前以多巴胺为中心的治疗旨在恢复患者的运动功能而不减慢疾病的进展。长期使用这些药物会导致疗效降低，运动波动和运动障碍。此外，多巴胺能治疗不能很好地解决与PD相关的非运动功能，例如睡眠障碍，疼痛和精神病症状。在过去的十年中，腺苷受体A2A拮抗剂已成为PD的潜在治疗方法。在这里，我们总结了腺苷受体A2A拮抗剂的最新研究成果（2015-2018年），并讨论了PD治疗的挑战和机遇。